oncology
FDA Approves Monjuvi for Relapsed or Refractory Follicular Lymphoma
The FDA approved Monjuvi with lenalidomide and rituximab for adults with relapsed or refractory follicular ...
JUNE 20, 2025
Meeting the Toxicity Challenge Posed by Antibody–Drug Conjugates
Antibody–drug conjugates have yielded improved survival rates in patients with gynecologic malignancies, but ...
JUNE 18, 2025
Medically Integrated Dispensing Is Best For Cancer Patients
Integrated care teams with in-house pharmacies can best help oncology patients obtain medications faster and with ...
MAY 23, 2025
Teledermoscopy Adds a Dose of Health Equity to Skin Cancer
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as ...
APRIL 24, 2025
Oncology Pharmacists a Valuable Addition to Cancer Care Team
A novel practice model that embeds oncology pharmacists in cancer clinics—where they educate patients about ...
APRIL 15, 2025
Precision Oncology Effort Blooms In North Carolina
Pharmacists at the University of North Carolina are increasing access to biomarker-driven cancer treatments via ...
APRIL 10, 2025
Polypharmacy in Cancer Not Just an Elder Patient Woe
Polypharmacy is highly prevalent among adults with cancer and multimorbidity, and is associated with high health ...
MARCH 22, 2025
Pharmacists a Critical Supplement to Safe CAM Use
Integrative oncology modalities such as vitamins and supplements, acupuncture, yoga and meditation can play an ...
MARCH 17, 2025
Automated Follow-up Alerts Pharmacists to Cancer Patients’ Needs
Early automated follow-up of cancer patients can help pharmacists more efficiently manage side effects of oral ...
JANUARY 28, 2025
Health-System Specialty Pharmacies Have Edge Over Unaffiliated Competitors
Filling prescriptions at health-system specialty pharmacies can help reduce primary medication nonadherence rates ...
JANUARY 24, 2025
Tevimbra Approved for Treatment of Gastric and Gastroesophageal Junction Cancers in Combination With Chemo
The FDA has approved Tevimbra, in combination with platinum and fluoropyrimidine-based chemotherapy, for the ...
JANUARY 13, 2025
Breakthrough in EGFR-Mutated NSCLC: Rybrevant Plus Lazcluze Extends Overall Survival
The bispecific antibody amivantamab-vmjw (Rybrevant, Janssen/Johnson & Johnson) plus lazertinib (Lazcluze, ...
JANUARY 10, 2025
